Drug updated on 1/19/2024
|Injection (intravenous; 1 mg/mL, 30 mg/30 mL single-dose vials)
|CD20-directed CD3 T-cell engagers
|Ongoing and Completed Studies
- For the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Product Monograph / Prescribing Information
|Lunsumio (mosunetuzumab-axgb) Prescribing Information.
|Genetech Inc., South San Francisco, CA
Systematic Reviews / Meta-Analyses
|Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy.
|Leukemia & Lymphoma
Clinical Practice Guidelines
|Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.
|Expert opinion on biological therapy